PBC2 - Overview: SP100 and GP210 Antibodies, IgG, Serum
Evaluating the risk of primary biliary cholangitis in anti-mitochondrial antibody (AMA)-negative patients by identification of Sp100 and gp210 antibodies Estimating risk in AMA-positive patients with incomplete feature of disease
PMPDD - Overview: PMP22 Gene, Large Deletion/Duplication Analysis, Varies
Diagnosis of Charcot-Marie-Tooth type 1A or hereditary neuropathy with liability to pressure palsies
MYEFL - Overview: Myelodysplastic Syndrome by Flow Cytometry, Bone Marrow
Detecting increased blasts Characterizing blast phenotypes Identifying abnormal patterns of myeloid maturation as seen in myelodysplastic syndromes and other clonal myeloid neoplasms Providing additional adjunct diagnostic information in...
RAVMP - Overview: Ravulizumab Monitoring Panel, Serum
Monitoring of complement blockage by ravulizumab Assessing the response to ravulizumab therapy Assessing the need for dose escalation Evaluating the potential for dose deescalation or discontinuation of therapy in remission...
FQPPS - Overview: Porphyrins, Feces
Evaluation of patients who present with signs or symptoms suggestive of porphyria cutanea tarda, hereditary coproporphyria, variegate porphyria, congenital erythropoietic porphyria, erythropoietic protoporphyria, or X-linked dominant...
Risk stratification of patients with treated multiple myeloma, which can assist in determining treatment and management decisions Risk stratification of patients with newly diagnosed multiple myeloma
PN10X - Overview: Pain Clinic Survey 10, Chain of Custody, Random, Urine
Detecting drug use involving amphetamines, barbiturates, benzodiazepines, cocaine, methadone, opiates, phencyclidine, and carboxy-tetrahydrocannabinol This chain-of-custody test is intended to be used in a setting where the test results...
Monitoring acute (ie, short-term) drug use in addiction treatment or pain management settings as part of a rotational drug testing strategy Presumptive screening for amphetamine, methamphetamine, opioids/opiates (targeting morphine,...
Risk stratification of patients with treated multiple myeloma, which can assist in determining treatment and management decisions Risk stratification of patients with newly diagnosed multiple myeloma
VWACT - Overview: von Willebrand Factor Activity, Plasma
Diagnosis of von Willebrand disease (VWD) and differentiation of VWD subtypes or differentiation of VWD from hemophilia A Monitoring therapeutic efficacy of treatment with DDAVP (desmopressin) or VWF concentrates in patients with VWD
Mayo Clinic Ranked No. 1 Hospital Nationwide by U.S. News & World Report - Insights
Report’s 29th annual "Best Hospitals Honor Roll" published online on August 14. Mayo Clinic also ranked No. 1 in more specialties than any other hospital in the country....
NELL-1 [Test in Focus] - Insights
D., discusses how Mayo Clinic Laboratories’ new immunohistochemistry test for the detection of NELL-1 antigen, a biomarker for membranous nephropathy found in 10% to 15% of patients, provides diagnostic...
Looking Back on Clinical Chemistry 1 - Insights
in the Mayo Clinic Medical Laboratory Science program, takes a look back on her Clinical Chemistry 1 course....
Detection of (1→3)-𝝱-D-glucan as a Marker of Invasive Fungal Disease - Insights
In this month’s “Hot Topic,” Elitza Theel, Ph.D., will discuss the detection of (1→3)-β-D-glucan (BDG) in serum as a biomarker for the presence of invasive fungal infections....
Orexin-A/Hypocretin-1 for the Diagnosis of Type 1 Narcolepsy [Test in Focus] - Insights
test to perform as well as to interpret. The orexin-A/hypocretin-1 test is a sensitive and specific alternative to the MSLT to diagnose type 1 narcolepsy....